Global Healthcare Analyst

Tina Banerjee

Equity Capital Markets

ImmuneOnco Biopharmaceuticals (Shanghai) / Equity Capital Markets

<ul>
<li>
<a href="https://www.smartkarma.com/entities/immuneonco-biopharmaceuticals-shanghai-inc" target="_blank" data-smartkarma-citation="entities:36080:1" rel="noopener">ImmuneOnco Biopharmaceuticals (Shanghai) (IOB HK)</a> has a differentiated next-generation immuno-oncology pipeline targeting a wide range of solid and hematologic tumors to address critical unmet medical needs.</li>
<li>The company's lead candidate IMM01 is being developed for the treatment of various hematologic malignancies and solid tumors as monotherapy and in combination with other agents.</li>
<li>The company has already undertaken a series of fund raising. Its current cash position can fund its operating expenses for more than two years, without the IPO proceeds.</li>
</ul>



ImmuneOnco Biopharmaceuticals (Shanghai) (IOB HK) has a differentiated next-generation immuno-oncology pipeline targeting a wide range of solid and hematologic tumors to address critical unmet medical needs.
The company's lead candidate IMM01 is being developed for the treatment of various hematologic malignancies and solid tumors as monotherapy and in combination with other agents.
The company has already undertaken a series of fund raising. Its current cash position can fund its operating expenses for more than two years, without the IPO proceeds.


ImmuneOnco Biopharmaceuticals (IOB HK) Pre-IPO: A Potentially Differentiated Oncology Portfolio

China

ImmuneOnco Biopharmaceuticals (Shanghai) (IOB HK)

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

ImmuneOnco Biopharmaceuticals (IOB HK) Pre-IPO: A Potentially Differentiated Oncology Portfolio

The company intends to list its shares on HK stock exchange. Investors, with high-risk appetite can consider this IPO for long-term investment due...

Tina Banerjee